{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:58:53Z","timestamp":1791824333484,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1331\/japha.2015.15017","type":"journal-article","created":{"date-parts":[[2015,9,26]],"date-time":"2015-09-26T18:30:16Z","timestamp":1443292216000},"page":"587-594","source":"Crossref","is-referenced-by-count":36,"title":["Community pharmacists\u2019 experience with pharmacogenetic testing"],"prefix":"10.1016","volume":"55","author":[{"given":"Jivan","family":"Moaddeb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne B.","family":"Haga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1331\/JAPhA.2015.15017_bb0005","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1056\/NEJMra1010600","article-title":"Genomics and drug response","volume":"364","author":"Wang","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1331\/JAPhA.2015.15017_bb0010","unstructured":"U.S. Food and Drug Administration. Table of pharmacogenomic biomarkers in drug labels. http:\/\/www.fda.gov\/Drugs\/ScienceResearch\/ResearchAreas\/Pharmacogenetics\/ucm083378.htm. Accessed May 14, 2015."},{"issue":"1","key":"10.1331\/JAPhA.2015.15017_bb0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ahj.2014.03.006","article-title":"CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients: rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study","volume":"168","author":"Bergmeijer","year":"2014","journal-title":"Am Heart J"},{"issue":"8","key":"10.1331\/JAPhA.2015.15017_bb0020","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/jama.2010.181","article-title":"Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation","volume":"303","author":"Breet","year":"2010","journal-title":"JAMA"},{"issue":"11","key":"10.1331\/JAPhA.2015.15017_bb0025","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.2217\/pgs.09.143","article-title":"Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations","volume":"10","author":"Ellis","year":"2009","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1331\/JAPhA.2015.15017_bb0030","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.nmd.2013.09.011","article-title":"Statin myotoxicity: a review of genetic susceptibility factors","volume":"24","author":"Needham","year":"2014","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"10.1331\/JAPhA.2015.15017_bb0035","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/clpt.2011.132","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450\u20132C19 (CYP2C19) genotype and clopidogrel therapy","volume":"90","author":"Scott","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1331\/JAPhA.2015.15017_bb0040","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/clpt.2014.125","article-title":"The clinical pharmacogenetics implementation consortium guideline for SL-CO1B1 and simvastatin-induced myopathy: 2014 update","volume":"96","author":"Ramsey","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1331\/JAPhA.2015.15017_bb0045","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/FPC.0000000000000028","article-title":"Comparison of delivery strategies for pharmacogenetic testing services","volume":"24","author":"Haga","year":"2014","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"10.1331\/JAPhA.2015.15017_bb0050","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1331\/JAPhA.2014.13033","article-title":"Implementation of a pharmacogenomics service in a community pharmacy","volume":"54","author":"Ferreri","year":"2014","journal-title":"J Am Pharm Assoc"},{"issue":"6","key":"10.1331\/JAPhA.2015.15017_bb0055","doi-asserted-by":"crossref","first-page":"e259","DOI":"10.1331\/JAPhA.2012.12108","article-title":"Making pharmacogenetic testing a reality in a community pharmacy","volume":"52","author":"O\u2019Connor","year":"2012","journal-title":"J Am Pharm Assoc"},{"issue":"4","key":"10.1331\/JAPhA.2015.15017_bb0060","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1177\/0897190014522496","article-title":"Pharmacogenetics in the community pharmacy: thienopyridine selection post-coronary artery stent placement","volume":"27","author":"Kisor","year":"2014","journal-title":"J Pharm Pract"},{"issue":"3","key":"10.1331\/JAPhA.2015.15017_bb0065","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1331\/154434506777069651","article-title":"Community pharmacists\u2019 work environments: evidence from the 2004 National Pharmacist Workforce Study","volume":"46","author":"Kreling","year":"2006","journal-title":"J Am Pharm Assoc"},{"issue":"1","key":"10.1331\/JAPhA.2015.15017_bb0070","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1331\/JAPhA.2015.14070","article-title":"Pharmacist-provided rapid HIV testing in two community pharmacies","volume":"55","author":"Darin","year":"2015","journal-title":"J Am Pharm Assoc"},{"issue":"5","key":"10.1331\/JAPhA.2015.15017_bb0075","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1331\/JAPhA.2012.11100","article-title":"Pharmacist-managed chronic obstructive pulmonary disease screening in a community setting","volume":"52","author":"Fuller","year":"2012","journal-title":"J Am Pharm Assoc"},{"issue":"3","key":"10.1331\/JAPhA.2015.15017_bb0080","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1071\/SH12069","article-title":"Chlamydia screening interventions from community pharmacies: a systematic review","volume":"10","author":"Gudka","year":"2013","journal-title":"Sex Health"},{"issue":"10","key":"10.1331\/JAPhA.2015.15017_bb0085","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/phar.1468","article-title":"Physician-pharmacist collaborative management of asthma in primary care","volume":"34","author":"Gums","year":"2014","journal-title":"Pharmacotherapy"},{"issue":"7","key":"10.1331\/JAPhA.2015.15017_bb0090","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S1553-7250(14)40039-4","article-title":"A clinical practice agreement between pharmacists and surgeons streamlines medication management","volume":"40","author":"Lovely","year":"2014","journal-title":"Jt Comm J Qual Patient Saf"},{"issue":"3","key":"10.1331\/JAPhA.2015.15017_bb0095","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/tpj.2011.1","article-title":"Survey of US public attitudes toward pharmacogenetic testing","volume":"12","author":"Haga","year":"2012","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"10.1331\/JAPhA.2015.15017_bb0100","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1089\/gtmb.2011.0045","article-title":"Professional perspectives about pharmacogenetic testing and managing ancillary findings","volume":"16","author":"Haga","year":"2012","journal-title":"Genet Test Mol Biomarkers"},{"key":"10.1331\/JAPhA.2015.15017_bb0105","series-title":"Pharm Times","article-title":"Pharmacists rank among most trusted professionals","author":"Oldfield","year":"2012"},{"issue":"2","key":"10.1331\/JAPhA.2015.15017_bb0110","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/ijpp.12126","article-title":"Why people seek advice from community pharmacies about skin problems","volume":"23","author":"Tucker","year":"2015","journal-title":"Int J Pharm Pract"},{"issue":"6","key":"10.1331\/JAPhA.2015.15017_bb0115","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/ijpp.12041","article-title":"Screening for major diseases in community pharmacies: a systematic review","volume":"21","author":"Ayorinde","year":"2013","journal-title":"Int J Pharm Pract"},{"issue":"1","key":"10.1331\/JAPhA.2015.15017_bb0120","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1186\/1471-2458-14-1139","article-title":"The feasibility and acceptability of the provision of alcohol screening and brief advice in pharmacies for women accessing emergency contraception: an evaluation study","volume":"14","author":"Brown","year":"2014","journal-title":"BMC Public Health"},{"issue":"1","key":"10.1331\/JAPhA.2015.15017_bb0125","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1331\/JAPhA.2015.14069","article-title":"Consumer interest in community pharmacy HIV screening services","volume":"55","author":"Darin","year":"2015","journal-title":"J Am Pharm Assoc"},{"issue":"2","key":"10.1331\/JAPhA.2015.15017_bb0130","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1177\/1715163513481555","article-title":"Key pharmacy indicators: capturing workload and measuring operational performance in a Canadian Forces clinic","volume":"146","author":"Dagenais","year":"2013","journal-title":"Can Pharm J"},{"key":"10.1331\/JAPhA.2015.15017_bb0135","unstructured":"National Center for Health Statistics. National ambulatory medical care survey: 2010 summary tables. http:\/\/www.cdc.gov\/nchs\/data\/ahcd\/namcs_summary\/2010_namcs_web_tables.pdf"},{"issue":"2","key":"10.1331\/JAPhA.2015.15017_bb0140","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1331\/154434506776180621","article-title":"Pharmacist involvement with immunizations: a decade of professional advancement","volume":"46","author":"Hogue","year":"2006","journal-title":"J Am Pharm Assoc"},{"issue":"4","key":"10.1331\/JAPhA.2015.15017_bb0145","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1331\/154434503322226211","article-title":"Pharmacy and immunization services: pharmacists\u2019 participation and impact","volume":"43","author":"Kamal","year":"2003","journal-title":"J Am Pharm Assoc"},{"issue":"6","key":"10.1331\/JAPhA.2015.15017_bb0150","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1331\/JAPhA.2008.07080","article-title":"Description of the characteristics of pharmacist-based immunization services in North Carolina: results of a pharmacist survey","volume":"48","author":"Kummer","year":"2008","journal-title":"J Am Pharm Assoc"},{"issue":"6","key":"10.1331\/JAPhA.2015.15017_bb0155","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1177\/1715163514552557","article-title":"Community pharmacist-administered influenza immunization improves patient access to vaccination","volume":"147","author":"Papastergiou","year":"2014","journal-title":"Can Pharm J"},{"issue":"2","key":"10.1331\/JAPhA.2015.15017_bb0160","first-page":"252","article-title":"Implementation of a pharmacy-based immunization program in a supermarket chain","volume":"40","author":"Weitzel","year":"2000","journal-title":"J Am Pharm Assoc"},{"issue":"4","key":"10.1331\/JAPhA.2015.15017_bb0165","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3390\/jpm2040201","article-title":"Insurance coverage policies for personalized medicine","volume":"2","author":"Hresko","year":"2012","journal-title":"J Pers Med"},{"key":"10.1331\/JAPhA.2015.15017_bb0170","unstructured":"Blue Cross Blue Shield of North Carolina. Corporate medical policy: cytochrome p450 genotyping. http:\/\/www.bcbsnc.com\/assets\/services\/public\/pdfs\/medicalpolicy\/cytochrome_p450_genotyping.pdf."},{"key":"10.1331\/JAPhA.2015.15017_bb0175","unstructured":"Local coverage document L35306\u2014pathology and laboratory: CYP2C19, CYP2D6, CYP2C9, and VKORC1 genetic testing (Cahaba Government Benefit Administrators). http:\/\/www.cms.gov\/medicare-coverage-database\/search\/document-id-search-results.aspx?Date=12\/01\/2014&DocID=L35306"},{"key":"10.1331\/JAPhA.2015.15017_bb0180","unstructured":"Local coverage document L34499\u2014MolDX: CYP2C19, CY-P2D6, CYP2C9, and VKORC1 genetic testing (Palmetto GBA). http:\/\/www.cms.gov\/medicare-coverage-database\/search\/document-id-search-results.aspx?Date=12\/01\/2014&DocID=L34499"},{"issue":"3","key":"10.1331\/JAPhA.2015.15017_bb0185","doi-asserted-by":"crossref","first-page":"51","DOI":"10.5688\/ajpe75351","article-title":"Assessment of the pharmacogenomics educational needs of pharmacists","volume":"75","author":"McCullough","year":"2011","journal-title":"Am J Pharm Educ"},{"issue":"2","key":"10.1331\/JAPhA.2015.15017_bb0190","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2217\/pgs.12.197","article-title":"An evaluation of pharmacists\u2019 expectations towards pharmacogenomics","volume":"14","author":"de Denus","year":"2013","journal-title":"Pharmacogenomics"},{"issue":"5","key":"10.1331\/JAPhA.2015.15017_bb0195","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1331\/JAPhA.2014.13041","article-title":"Implementation of personalized medicine services in community pharmacies: perceptions of independent community pharmacists","volume":"54","author":"Alexander","year":"2014","journal-title":"J Am Pharm Assoc"},{"issue":"12","key":"10.1331\/JAPhA.2015.15017_bb0200","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1056\/NEJM199703203361202","article-title":"The use and interpretation of commercial APC gene testing for familial adenomatous polyposis","volume":"336","author":"Giardiello","year":"1997","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1331\/JAPhA.2015.15017_bb0205","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/jmg.2004.030296","article-title":"Hereditary breast\/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians","volume":"42","author":"Wideroff","year":"2005","journal-title":"J Med Genet"},{"issue":"2","key":"10.1331\/JAPhA.2015.15017_bb0210","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2353\/jmoldx.2009.080130","article-title":"Clinician perspectives about molecular genetic testing for heritable conditions and development of a clinician-friendly laboratory report","volume":"11","author":"Lubin","year":"2009","journal-title":"J Mol Diagn"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319116300024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319116300024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T21:03:30Z","timestamp":1567199010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319116300024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S1544319116300024"],"URL":"https:\/\/doi.org\/10.1331\/japha.2015.15017","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]}}}